Scope
This NICE guideline (NG110) covers antimicrobial prescribing for acute prostatitis. It describes the condition and recommends obtaining a urine culture, offering antibiotics, and reviewing treatment against culture results. It also covers patient advice, reassessment, hospital referral, self-care, and oral and intravenous antibiotic choices for adults aged 18 years and over, including 14-day review points. The committee states that no efficacy studies were identified, so recommendations rest on committee experience, other guidelines and resistance data.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognition and initial assessment
- Acute prostatitis is a bacterial infection of the prostate requiring antibiotics. It usually arises from urinary tract bacteria and may occur spontaneously or after procedures such as prostate biopsy. Complications include acute urinary retention and prostatic abscess. [1]
- Send a midstream urine sample for culture and susceptibility testing before the person takes antibiotics. [1]
Antibiotic treatment principles
- Offer antibiotics to people with acute prostatitis. When doing so, weigh symptom severity and the risk of complications or treatment failure, especially after procedures such as prostate biopsy. Also consider earlier culture and susceptibility results and past antibiotic exposure that may have selected resistant bacteria. [1]
- When urine culture results are available, review the antibiotic. If the organism is resistant, switch according to susceptibilities, preferring a narrow-spectrum agent wherever possible. [1]
- Base prescribing on local antimicrobial resistance data from Public Health England and on table 1, which applies to adults aged 18 years and over. Check previous culture results and prior prescribing when choosing. [1]
- Use oral antibiotics first line when the person can take oral medicines and illness severity does not call for intravenous therapy. [1]
Oral antibiotic choice (adults 18 and over)
- First-choice oral options, guided by susceptibilities when available, are ciprofloxacin 500 mg twice daily or ofloxacin 200 mg twice daily, each for 14 days then review. The table directs prescribers to the MHRA January 2024 advice on restrictions and precautions for fluoroquinolones because of the risk of disabling and potentially long-lasting or irreversible side effects. [1]
- If a fluoroquinolone is not appropriate, trimethoprim 200 mg twice daily for 14 days then review is the alternative first choice. The table advises seeking specialist advice, with choice guided by susceptibilities when available. [1]
- Second-choice oral levofloxacin 500 mg once daily for 14 days then review is reserved for use after discussion with a specialist. The table again refers to the MHRA January 2024 advice on fluoroquinolone restrictions and precautions because of the risk of disabling and potentially long-lasting or irreversible side effects. [1]
- Co-trimoxazole 960 mg twice daily for 14 days then review is the other second-choice oral option after discussion with a specialist. It should be considered only when there is bacteriological evidence of sensitivity and good reasons to prefer this combination to a single antibiotic. [1]
- The committee regards fluoroquinolones as appropriate for this severe infection but says safety concerns should be weighed for each patient. Their interaction with NSAIDs may increase seizure risk. [1]
Intravenous antibiotics
- First-choice IV antibiotics are for people unable to take oral antibiotics or who are severely unwell, with choice guided by susceptibilities when available. Antibiotics may be combined if sepsis is a concern. [1]
- First-choice IV fluoroquinolone options are ciprofloxacin 400 mg two or three times daily or levofloxacin 500 mg once daily. The table refers to the MHRA January 2024 advice on fluoroquinolone restrictions and precautions because of the risk of disabling and potentially long-lasting or irreversible side effects. [1]
- First-choice IV cephalosporin options are cefuroxime 1.5 g three or four times daily or ceftriaxone 2 g once daily. [1]
- Gentamicin is a first-choice IV option for people who are severely unwell or unable to take oral antibiotics. Start at 5 mg/kg to 7 mg/kg once daily and adjust later doses according to serum gentamicin concentration; therapeutic drug monitoring and renal function assessment are required. [1]
- Amikacin is the other first-choice IV aminoglycoside for this group. Start at 15 mg/kg once daily, up to a maximum of 1.5 g per dose, and adjust later doses according to serum amikacin concentration, up to a maximum of 15 g per course. Therapeutic drug monitoring and renal function assessment are required. [1]
- For second-choice IV therapy, consult a local microbiologist. Use the BNF for appropriate use and dosing in specific populations such as hepatic or renal impairment, and for administering IV antibiotics. [1]
Review and duration
- Review IV antibiotics by 48 hours and consider stepping down to oral therapy where possible, for a total of 14 days followed by review. [1]
- At 14 days, either stop antibiotics or continue for a further 14 days if needed. Base this on history, symptoms, examination, and urine and blood tests. The committee notes that persisting fever or lower urinary tract symptoms need ongoing treatment. [1]
Advice, reassessment and referral
- When prescribing, explain that illness usually lasts several weeks and warn about antibiotic adverse effects, notably diarrhoea and nausea. Advise seeking help if symptoms worsen, fail to begin improving within 48 hours of taking the antibiotic, or the person becomes systemically very unwell. [1]
- Reassess anyone whose symptoms worsen. Consider alternative diagnoses, features of serious illness such as urinary retention, prostatic abscess or sepsis, and prior antibiotic use that may have selected resistant bacteria. [1]
- Refer to hospital if there are signs of more serious illness, such as sepsis, urinary retention or prostatic abscess. Also refer if symptoms are not improving 48 hours after antibiotics are started. [1]
Self-care
Limitations and use
- The antibiotic table covers only adults aged 18 years and over; no dosing is given for younger people.
- No systematic reviews, RCTs or observational studies of antibiotic or non-antimicrobial efficacy were identified; recommendations rest on committee experience, other guidelines and resistance data.
- The guideline makes no recommendation on antibiotic prophylaxis after prostate biopsy, because the evidence was judged insufficient; the committee advises consulting local microbiologists.
- Second-choice intravenous options are not specified; local microbiologist input is advised.
- Dosing in specific populations, such as hepatic or renal impairment, is deferred to the BNF.
- The external MHRA January 2024 fluoroquinolone advice and the BNF monographs referenced in the antibiotic table are not reproduced in the source and must be consulted separately.
- Resistance data cited are national figures for England; prescribers are directed to local data.
- Research recommendations and later rationale or update sections were not included in the reviewed text.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Prostatitis (acute): antimicrobial prescribing
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 31 October 2018
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.